Open array design: To translate the classifier that was build based on exon array data to a clinically applicable platform, we decided to measure expression of the desired transcripts using RT-qPCR assay. We searched for commercially available TaqMan assays on Life Technology Inc. website.
For the qPCR analysis, the cDNA (the RT reaction) was mixed with OpenArray real time RT-PCR master mix (Applied Biosystems Inc.) in the 384 well OpenArray loading plates as per the plate map and instructions for 168 plate format OpenArray RT-qPCR assay. The Openarray set using an autoloader loads the Openarray plate which is then run on the OpenArray TM NT cycler to collect data.
Each 168-format OpenArray plate can estimate the expression of upto168 transcripts/genes for 16 samples and three OpenArray plates can be run together on the cycler. The expression of the transcripts in GBM samples as fold changes was calculated relative to normal brain tissue using POLR2A as the normalization control based on the deldelct method. Figure S1 : Kaplan-Meier survival curve for gene expression based GBM sub-types defined by Verhaak and colleagues for the 173 TCGA core GBM patients. The four subtypes do not show statistically significant (p=0.39) differences with respect to patient outcome. Figure S2 : Identification of number of stable clusters for molecular subtyping of GBM patients.
Supplementary Figures:
Consensus NMF clustering was applied on the isoform-level expression matrix for the 419 GBM patients from TCGA cohort and the cophenetic correlation coefficient (represents cluster stability) for various k-factor (2-7) factorization rank was plotted (A) along with the heatmap for the visualization of clustering at k=2,3,4 and 5 (B). Boxplot represents the expression as fold change from RNA-seq data for the marker genes of the four different subtypes in TCGA-cohort of GBM patients (155) identified by our classifier. The y-axis for MET is shown in logarithmic scale. All fold changes were calculated relative to normal brain tissue and statistical significance was determined by two sample t-test. Tables:   Table S1 . TCGA GBM patient cohort exon array data used in this study. Table S3 : The list of transcripts and the corresponding genes included in the RT-qPCR based assay for GBM subtyping.
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Endogenous controls GAPDH POLR2A* * used for normalization Table S4 : The output of our classifier that was applied on the RNA-seq data for the 155 GBM patients from TCGA. For each sample, the classifier calculates the probabilities that it belongs to one of the four subtypes, and the algorithm assigns the sample to the subtype with the highest probability. The exon-array data based label and the NMF clustering determined true labels for the overlapping 76 samples (in bold) between the isoform based core samples and RNA-seq dataset are also presented. The confusion matrix when our classifier was applied on the RNA-seq data for the 76 GBM patients from TCGA for whom exon-array expression data was also available. Table S7 : The output of our classifier that was applied on the RT-qPCR based assay data obtained on the GBM samples from Penn-cohort. For each sample, the classifier calculates the probabilities that it belongs to one of the four subtypes, and the algorithm assigns the sample to the subtype with the highest probability. 
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